BUZZ-Microcap Monopar Therapeutics tumbles on planned stock offering
** Shares of Monopar Therapeutics tumble ~18% to $14.65 post-market after co unveils planned equity raise ** Co announces stock offering on best effort basis; deal size not disclosed
** It plans to use net proceeds for general purposes, including R&D, clinical trial expenditures, among other uses
** Co has 3.9 mln shares outstanding for ~$70 mln market cap and ~2 mln shares of free float, per LSEG
** MNPR closed Monday's session up 5.3% at $17.83 ** On Thurs, stock surged seven-fold from $4.63 to close at $32.66 after co inked licensing deal with AstraZeneca for AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Rodman & Renshaw exclusive placement agent for stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@thomsonreuters.com lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available